RNA Therapeutics Discovery and Translation Program recharge facility.
Mayo Clinic researchers have access to a wide array of technologies in the RNA Therapeutics Discovery and Translation Program's recharge facility.
Recharge facility
The RNA Therapeutics Discovery and Translation Program recharge facility houses cutting-edge technology to support the development of novel RNA therapies. The facility supports and advances oligonucleotide, messenger RNA (mRNA) and lipid nanoparticle-based approaches to help create new opportunities for discovery by researchers and advance the scope of RNA-DNA therapeutics beyond current paradigms.
Facility capabilities support three core technologies:
- Oligonucleotide synthesis. Design and produce short, sequence-specific, fully modified oligonucleotide products, including antisense oligonucleotides (ASOs), small interfering RNAs and aptamers.
- mRNA synthesis. Automate in vitro transcription of mRNA constructs for therapeutic protein expression and gene editing applications.
- Lipid nanoparticle synthesis. Formulate lipid-based nanoparticles to encapsulate and deliver RNA molecules efficiently and safely to target cells and tissues.
The recharge facility offers advanced technology to quickly and precisely synthesize, purify and characterize research-grade RNA molecules.
Contact